BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16263297)

  • 1. Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series.
    Rivara M; Zuliani V; Cocconcelli G; Morini G; Comini M; Rivara S; Mor M; Bordi F; Barocelli E; Ballabeni V; Bertoni S; Plazzi PV
    Bioorg Med Chem; 2006 Mar; 14(5):1413-24. PubMed ID: 16263297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists.
    Mor M; Bordi F; Silva C; Rivara S; Zuliani V; Vacondio F; Rivara M; Barocelli E; Bertoni S; Ballabeni V; Magnanini F; Impicciatore M; Plazzi PV
    Bioorg Med Chem; 2004 Feb; 12(4):663-74. PubMed ID: 14759727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
    Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
    Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
    J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
    Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold.
    Morini G; Comini M; Rivara M; Rivara S; Lorenzi S; Bordi F; Mor M; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4063-7. PubMed ID: 16713264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type.
    Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T
    Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Camelin JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2009 Apr; 17(8):3037-42. PubMed ID: 19329325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
    Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG
    J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists.
    Lorenzi S; Mor M; Bordi F; Rivara S; Rivara M; Morini G; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV
    Bioorg Med Chem; 2005 Oct; 13(19):5647-57. PubMed ID: 16085419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
    Rivara S; Mor M; Bordi F; Silva C; Zuliani V; Vacondio F; Morini G; Plazzi PV; Carrupt PA; Testa B
    Drug Des Discov; 2003; 18(2-3):65-79. PubMed ID: 14675944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of HB-donor groups in the heterocyclic polar fragment of H3-antagonists. I. Synthesis and biological assays.
    Zuliani V; Bordi F; Rivara M; Silva C; Vacondio F; Morini G; Rivara S; Barocelli E; Ballabeni V; Bertoni S; Magnanini F; Plazzi PV
    Farmaco; 2003 Sep; 58(9):891-9. PubMed ID: 13679184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperidine variations in search for non-imidazole histamine H(3) receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Schwartz JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2008 Sep; 16(18):8729-36. PubMed ID: 18774720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
    J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
    Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.